Cidara Therapeutics Gears Up for Upcoming Biotech Conference
Cidara Therapeutics, Inc. (NASDAQ: CDTX), based in San Diego, is making waves in the biotechnology sector with its innovative proprietary platform known as Cloudbreak. This platform specializes in developing drug-Fc conjugate (DFC) immunotherapies with a mission to enhance the standard of care for patients facing severe health challenges. Recently, the company announced an exciting opportunity: its President and CEO, Jeffrey Stein, Ph.D., is set to participate in an influential biotech conference.
Event Details
The event is the Guggenheim Securities SMID Cap Biotech Conference, a notable gathering for investors interested in small and mid-cap biotechs. The conference is scheduled for February and will feature a variety of discussions and presentations.
Conference Format
The format will include a fireside chat, creating an engaging environment for dialogue. This setting typically allows for more in-depth discussions on strategy, innovation, and market trends.
Watch the Presentation
For those interested in the conversation, a webcast will be available. This unique feature ensures that even those unable to attend in person can still experience the insights shared at the conference. The replay of this presentation will be accessible on Cidara's Investor page for 90 days.
Investors Interested in One-on-One Meetings
In addition to the conference presentation, Cidara will engage in one-on-one meetings with potential investors, making it a prime opportunity for stakeholders to directly connect with the company. Interested parties are encouraged to reach out to their Guggenheim representatives to schedule these discussions.
Cidara's Drug Development Pipeline
Cidara has made significant strides in their drug development pipeline, particularly with their lead DFC candidate, CD388. This innovative treatment aims to revolutionize antiviral care by providing universal prevention for seasonal and pandemic influenza. The company's focus on efficiency and effectiveness in immunotherapy development positions it as a leader in biotechnology.
Regulatory Recognition
The U.S. Food and Drug Administration (FDA) granted Fast Track Designation for CD388, recognizing its potential as a crucial tool in combating influenza. This approval can expedite the development timeline, emphasizing the promise that Cidara's research holds.
Oncology Ventures
Furthermore, Cidara is also exploring avenues in oncology, with another DFC project, CBO421, which recently received Investigational New Drug (IND) clearance. Designed to target CD73 in solid tumors, this project further showcases Cidara's commitment to expanding its therapeutic reach.
About Cidara Therapeutics
Founded on innovative ideas, Cidara aims to bridge gaps in treatment by utilizing its Cloudbreak platform for developing targeted, effective medications. The company remains dedicated to improving patient outcomes through advanced research and collaborations.
Investor and Media Contact Information
For those seeking further information, Cidara's investor contact is Brian Ritchie from LifeSci Advisors. He can be contacted at (212) 915-2578 or by email. Media inquiries should be directed to Michael Fitzhugh at LifeSci Communications, also available via email.
Frequently Asked Questions
What is the purpose of the Guggenheim Securities SMID Cap Biotech Conference?
The conference serves as a platform to showcase small to mid-cap biotech firms, offering insights into their research and investment opportunities.
Who will represent Cidara Therapeutics at the conference?
Jeffrey Stein, Ph.D., the President and CEO of Cidara Therapeutics, will be participating in discussions at the conference.
Where can I watch the webcast of the conference presentation?
The webcast will be available on Cidara's Investor page, allowing for remote access to the presentation.
What is the significance of Cidara's CD388 candidate?
CD388 is designed for universal prevention of influenza, with Fast Track Designation granting it potential expedited review by the FDA.
How can investors arrange a meeting with Cidara representatives?
Investors interested in meetings should contact their Guggenheim representative directly to arrange discussions with Cidara's team.
